Accepting the caveats concerning possible confounding influence from diet and cell death [1], the measurement of in urine is thought to provide a non-invasive assessment of whole body oxidative stress. This represents a number of advantages over other possible biomarkers of oxidative stress. The non-invasive nature of the assay make it less of an ethical issue than, for example, bloodbased assessments of oxidative stress, in particular when sampling from vulnerable groups is required. Many of the issues of adventitious damage, associated with the study of cellular 8-oxodG [2], are circumvented by analysis of urine. Urine is easily collected and transported.No special storage conditions are required, for example no preservatives are necessary, with 8-oxodG reported to be stable in urine, at -20 °C, for over 10 years [3], making previously collected samples eminently suitable for analysis. Such urinary biomarkers can therefore be used in both prospective and nested, case-control molecular epidemiology studies [4]. Data concerning the antigens recognised by the primary antibody of the JaICA kit (denoted N45.1) suggest the antibody to be highly specific for 8-oxodG [26]. This, in part, derives from recognition of the hydroxylated C8 position of Gua, it would appear to discriminate the C6 carbonyl group of 8-oxoGua (and C2 NH 2 ), from the C6 amino group of 8-oxoAde. Furthermore, the closest competitors, other than 8-oxodG, for the antibody is 8-oxo-7,8-dihydroguanosine (8-oxoGuo) and 8-oxodGMP [25], the former of which needs to be present in concentrations two orders of magnitude higher than 8-oxodG, in order to compete to the same extent [26], a situation that does not appear to occur in vivo [27]. It is unknown whether 8-oxodGMP is present in urine. Toyokuni et al. [26] also reported that other endogenous constituents, present at high concentrations, in urine, such as uric acid, urea and creatinine, show no cross-reactivity with the antibody. Biology and Medicine, Song et al. [28] demonstrate that urea is, in fact, one of the major contributors to the over-estimation of urinary 8-oxodG by ELISA. The authors' approach to better understand the reactivity of N45.1 is to fractionate a human urine sample, and to test aliquots of these fractions for reactivity in the ELISA. The first eluting ELISA-positive fractions was, using retention time as a guide, surmised to contain urea and allantoin, the second fraction contained 8-oxodG. Both urea and allantoin were then screened in the ELISA, with urea demonstrating competition with 8-oxodG for antibody binding. This raises the question 'why this was not noted during antibody characterisation?'. In the work of Song et al. [28], a urea concentration of 10-80 mg/mL was used, levels similar to that seen in human urine. In contrast, the concentrations used during the characterisation of N45.1 were four orders of magnitude lower than that present in human urine, explaining the apparent lack of reactivity [26]. This raises the possibility that urease treatment of urine, prior to...